Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

[Additional advantages of mexicor used in combined therapy of coronary heat disease and diabetes mellitus of 2nd type].

Statsenko ME, Turkina SV, Kosivtseva MA.

Klin Med (Mosk). 2013;91(5):59-64. Russian.

PMID:
24159791
2.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

3.
4.
5.

[Prevalence of inapropriate LDL cholesterol levels in patients with coronary disease and/or type 2 diabetes].

Pérez de Isla L, Saltijeral Cerezo A, Vitale G, González Timón B, Torres Do Rego A, Alvarez-Sala Walther LA.

Rev Clin Esp. 2012 Nov;212(10):475-81. doi: 10.1016/j.rce.2012.07.003. Epub 2012 Oct 5. Spanish.

PMID:
23044423
6.

Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.

Chapman RH, Petrilla AA, Berman L, Benner JS, Tang SS.

Am J Cardiovasc Drugs. 2009;9(5):299-308. doi: 10.2165/11312110-000000000-00000.

PMID:
19791839
7.
8.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
9.

Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients.

Kojima S, Sakamoto T, Ogawa H, Kitagawa A, Matsui K, Shimomura H, Kimura K, Ogata Y, Sakaino N; Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors Investigators.

Circ J. 2010 Apr;74(4):779-85. Epub 2010 Feb 17.

10.

Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.

De Luis DA, Romero E, Aller R, Izaola O.

Clin Nutr. 2000 Oct;19(5):367-70.

PMID:
11031077
11.

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.

Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U.

Eur J Gastroenterol Hepatol. 2010 Jan;22(1):18-23. doi: 10.1097/MEG.0b013e32832e2baf.

PMID:
19667999
12.

Non-alcoholic fatty liver disease and the statins treatment.

Dima A, Marinescu AG, Dima AC.

Rom J Intern Med. 2012 Jan-Mar;50(1):19-25. Review.

PMID:
22788090
13.

[Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].

Lazebnik LB, Zvenigorodskaia LA, Egorova EG, Mel'nikova NV, Khomeriki SG.

Eksp Klin Gastroenterol. 2009;(8):4-11. Russian.

PMID:
20469672
15.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
16.

High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease.

Lu H, Zeng L, Liang B, Shu X, Xie D.

Arch Med Res. 2009 Oct;40(7):571-5. doi: 10.1016/j.arcmed.2009.07.009. Epub 2009 Sep 25.

PMID:
20082871
17.
18.

[The influence of statin therapy on circulating microRNA-92a expression in patients with coronary heart disease].

Wang H, Lu HM, Yang WH, Luo C, Lu SH, Zhou Y, Lin YZ.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Apr;24(4):215-8. Chinese.

19.

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease.

Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T.

J Gastroenterol. 2009;44(10):1064-70. doi: 10.1007/s00535-009-0091-1. Epub 2009 Jun 17.

PMID:
19533014
20.

Statin therapy in the primary and secondary prevention of coronary artery disease in patients with type 2 diabetes. A scientific review.

Paulo S, Fernandes S, Vizinho R, Carneiro AV.

Rev Port Cardiol. 2004 Nov;23(11):1461-82. Review. English, Portuguese.

Supplemental Content

Support Center